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Summary
 
CD7 is an immunoglobulin superfamily molecule involved in T and natural killer (NK) cell ac-
tivation and cytokine production. CD7-deficient animals develop normally but have antigen-
specific defects in interferon (IFN)-
 
g
 
 production and CD8
 
1
 
 CTL generation. To determine
the in vivo role of CD7 in systems dependent on IFN-
 
g
 
, the response of CD7-deficient mice to
lipopolysaccharide (LPS)-induced shock syndromes was studied. In the high-dose LPS-induced
shock model, 67% of CD7-deficient mice survived LPS injection, whereas 19% of control
C57BL/6 mice survived LPS challenge (
 
P
 
 , 
 
0.001). CD7-deficient or C57BL/6 control mice
were next injected with low-dose LPS (1 
 
m
 
g plus 8 mg D-galactosamine [D-gal] per mouse)
and monitored for survival. All CD7-deficient mice were alive 72 h after injection of LPS
compared with 20% of C57BL/6 control mice (
 
P
 
 , 
 
0.001). After injection of LPS and D-gal,
CD7-deficient mice had decreased serum IFN-
 
g
 
 and tumor necrosis factor (TNF)-
 
a
 
 levels
compared with control C57BL/6 mice (
 
P
 
 , 
 
0.001). Steady-state mRNA levels for IFN-
 
g
 
 and
TNF-
 
a
 
 in liver tissue were also significantly decreased in CD7-deficient mice compared with
controls (
 
P
 
 , 
 
0.05). In contrast, CD7-deficient animals had normal liver interleukin (IL)-12,
IL-18, and interleukin 1 converting enzyme (ICE) mRNA levels, and CD7-deficient spleno-
cytes had normal IFN-
 
g
 
 responses when stimulated with IL-12 and IL-18 in vitro. NK1.1
 
1
 
/
CD3
 
1
 
 T cells are known to be key effector cells in the pathogenesis of toxic shock. Phenotypic
analysis of liver mononuclear cells revealed that CD7-deficient mice had fewer numbers of
liver NK1.1
 
1
 
/CD3
 
1
 
 T cells (1.5 
 
6
 
 0.3 
 
3 
 
10
 
5
 
) versus C57BL/6 control mice (3.7 
 
6
 
 0.8 
 
3
 
10
 
5
 
; 
 
P
 
 
 
, 
 
0.05), whereas numbers of liver NK1.1
 
1
 
/CD3
 
2
 
 NK cells were not different from
controls. Thus, targeted disruption of CD7 leads to a selective deficiency of liver NK1.1
 
1
 
/
CD3
 
1
 
 T cells, and is associated with resistance to LPS shock. These data suggest that CD7 is a
key molecule in the inflammatory response leading to LPS-induced shock.
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D7 is a 40-kD member of the Ig gene superfamily that
is expressed on a major subset of human peripheral T
lymphocytes and NK cells (1–7). CD7 is an early T cell ac-
tivation antigen in that CD7 mRNA levels rise within 15
min after initiation of a transmembrane calcium ion flux
(8). CD7 can complex with CD3 and CD45 molecules (9),
and CD7 signaling involves both protein kinase C and pro-
tein tyrosine kinase (6, 10). CD7 has been shown to be a
functional signal-transducing molecule on resting NK cells
(6, 11). Antibody cross-linking of NK cell CD7 induced
increases in free cytoplasmic calcium, secretion of IFN-
 
g
 
,
NK cell proliferation, adhesion to fibronectin, and NK cy-
totoxic activity (6). Although the above studies have dem-
onstrated in vitro roles for CD7 in T and NK cell activa-
tion and/or adhesion, relevant functions of CD7 in vivo
remain unknown.
To probe in vivo functional roles of CD7 in the murine
immune system, CD7-deficient mice were generated using
homologous recombination techniques (12). We have pre-
viously shown that CD7-deficient animals had decreased in
vitro antigen-specific IFN-
 
g
 
 production, and had dimin-
ished antigen-driven CD8
 
1
 
 CTL activity (12).
Use of genetically deficient mice has been instrumental
in identifying the roles of cytokines in LPS-induced shock.
The low-dose LPS shock model takes advantage of the in-
creased susceptibility of mice to 1 
 
m
 
g of LPS after injection
with 8 mg of D-galactosamine (D-gal) (13, 14). IFN-
 
g
 
 and
TNF-
 
a
 
 are key mediators of hepatocyte necrosis and death 
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in the low-dose LPS shock model (15–18). In the high-
dose LPS shock model, administration of 100 mg/kg of
LPS results in increased levels of serum inflammatory cyto-
kines, neutrophil infiltration, and aggregation in liver and
other tissues, and death within 3–5 d (14). Intracellular ad-
hesion molecule (ICAM)-1, IL-1, and TNF-
 
a
 
 are key me-
diators of the lethal effects of high-dose LPS (19–22).
In this study, we have determined the sensitivity of
CD7-deficient mice to LPS-induced shock syndromes. We
found that CD7-deficient mice were completely resistant
to death in the low-dose LPS shock model, and they were
partially resistant to death in the high-dose LPS shock
model.
 
Materials and Methods
 
Animals and Treatments.
 
Homozygous CD7-deficient mice
(12) were backcrossed five generations onto the C57BL/6 back-
ground. C57BL/6 mice were obtained from The Jackson Labo-
ratory. 10–12-wk-old sex-matched mice were studied. Phenol
extracted LPS from 
 
Escherichia coli
 
 (Sigma Chemical Co.) was ad-
ministered intraperitoneally at 100 mg/kg for the high-dose LPS
shock model. For the low-dose LPS plus D-gal (Sigma Chemical
Co.) shock model, animals received 1 
 
m
 
g of LPS and 8 mg D-gal
intraperitoneally in 0.5 ml saline. Animals were killed and livers
and spleens were excised and studied as indicated below. Mouse
handling and experimental procedures were conducted in accor-
dance with the American Association of Accreditation of Labora-
tory Animal Care guidelines for animal care and use.
 
Cytokine Measurements.
 
Quantification of murine IFN-
 
g
 
 and
TNF-
 
a
 
 present in sera and culture supernatants was determined
using Duoset cytokine-specific ELISA kits as per the manufac-
turer’s protocols (Genzyme Corp.).
 
In Vitro Splenocyte Cultures.
 
Splenocytes were stimulated with
murine recombinant (r)IL-12 (Genzyme Corp.) and murine rIL-18
(Chemicon) in RPMI 1640 with 
 
l
 
-glutamine (GIBCO BRL)
supplemented with 10% FCS, 5.5 
 
3 
 
10
 
2
 
5
 
 M 2-ME, and 10 
 
m
 
g/ml
gentamicin (BioWhittaker) for 3 d at 10
 
6
 
 cells/ml in tissue culture
plates (Costar) at 37
 
8
 
C in a 5% CO
 
2
 
 humidified incubator.
 
RNA Isolation and RNase Protection Assays.
 
Total RNA was
isolated from spleen and liver tissue using Trizol (GIBCO BRL)
as per the manufacturer’s protocol. Steady-state levels of specific
cytokine messenger RNA in tissues were determined using the
multiprobe RiboQuant RNase Protection Assay (PharMingen).
 
Isolation of Liver Lymphocytes and Flow Cytometry.
 
Liver lym-
phocytes were prepared as previously described (23). Phenotypic
analysis of liver lymphocytes (10
 
6
 
 cells in 50 
 
m
 
l) was performed at
4
 
8
 
C after an initial blocking step with 1 
 
m
 
g of unlabeled anti-
Fc
 
g
 
R Ab (PharMingen). mAbs used included CD3 (Caltag),
NK1.1 (PharMingen), and B220 (Caltag).
 
Statistical Analysis.
 
Student’s 
 
t
 
 test was used to determine sig-
nificance of cytokine mRNA and protein levels. Chi-square tests
were used to determine 
 
P
 
 values for mouse survival data.
 
Results
 
CD7-deficient Mice Are Resistant to LPS-Induced Shock
Syndromes.
 
To determine the effect of high-dose LPS
treatment in CD7-deficient mice, CD7-deficient mice (
 
n
 
 5
 
30) and C57BL/6 control (
 
n
 
 5 
 
16) mice were injected in-
traperitoneally with LPS (100 mg/kg) and survival was as-
sessed daily for 7 d (Fig. 1 A). C57BL/6 mice succumbed to
shock between days 1 and 2 after high-dose LPS injection,
with only 19% of the animals surviving on day 7. In con-
trast, 67% of CD7-deficient animals were alive on day 7
(
 
P
 
 , 
 
0.001), and demonstrated partial resistance to high-dose
LPS shock. As additional controls, saline injected CD7-defi-
cient (
 
n
 
 5 
 
3) and C57BL/6 control mice (
 
n
 
 5 
 
3), remained
alive and healthy throughout the 7-d study (Fig. 1 A).
Within 12 h of intraperitoneal injection of low-dose LPS
(1 
 
m
 
g) and D-gal (8 mg), only 20% of control C57BL/6
animals (
 
n
 
 5 
 
10) survived (Fig. 1 B), consistent with previ-
ously reported data for this model (13). In contrast, no
deaths were observed in CD7-deficient mice (
 
n
 
 5 
 
10) up
to 72 h after injection with LPS (
 
P
 
 , 
 
0.001). Because of
the total resistance of CD7-deficient mice to death in the
low-dose LPS shock syndrome model, we studied this
model further.
 
Elevated Serum Levels of TNF-
 
a
 
 and IFN-
 
g
 
 in the Low-
Dose LPS Shock Model Are Dependent on CD7 Expression.
 
Studies using IFN-
 
g
 
R–deficient (15) and TNFRI-deficient
(16, 18) mice have clearly demonstrated the importance of
IFN-
 
g
 
 and TNF-
 
a
 
 as dominant cytokines that induce hep-
Figure 1. Survival of CD7-deficient mice treated with LPS. (A) High-
dose shock model. C57BL/6 control (j, n 5 16) and CD7-deficient
mice (h, n 5 30) were injected intraperitoneally with LPS (100 mg/kg).
Control C57BL/6 (s, n 5 3) and CD72/2 mice (m, n 5 3) were injected
intraperitoneally with saline. Mortality was assessed daily for 7 d. (B)
Low-dose LPS plus D-gal shock model. C57BL/6 control mice (j, n 5
10) and CD7-deficient mice (h, n 5 10) were injected intraperitoneally
with LPS (1 mg) and D-gal (8 mg) in saline. Mortality was assessed for 3 d;
*P  #  0.001 when comparing survival of C57BL/6 control mice to
CD7-deficient mice.1013 Sempowski et al. Brief Definitive Report
atitis and death in the low-dose LPS shock model (14).
Therefore, serum levels of TNF-a and IFN-g were mea-
sured in control C57BL/6 and CD7-deficient mice at mul-
tiple time points after injection of LPS and D-gal (Fig. 2).
There was a sharp increase in serum TNF-a levels in
C57BL/6 animals 1 h after LPS plus D-gal treatment, that
fell to baseline after 4 h of treatment (Fig. 2 A). In contrast,
a blunted peak in TNF-a secretion was observed in CD7-
deficient mice 1 h after LPS plus D-gal treatment, with a
rapid return to baseline 2 h after treatment. Peak TNF-a
serum levels in CD7-deficient animals were 55 6 7% of
that of control animals (P , 0.001) with a decrease in se-
rum TNF-a levels 2 h after LPS plus D-gal treatment.
In contrast to the early 2 h rise in TNF-a, serum IFN-g
levels in C57BL/6 mice peaked 6 h after injection of LPS
plus D-gal (Fig. 2 B). Importantly, a near complete absence
of serum IFN-g was observed in CD7-deficient mice at the
same time point (P , 0.001), and throughout the entire
12-h study period. Thus, disruption of the CD7 gene re-
sulted in a partial block in serum TNF-a production, and
in a complete block in serum IFN-g production in the
low-dose LPS-induced shock model.
IFN-g and TNF-a Cytokine mRNA Expression Was De-
creased in Liver from LPS-Treated CD7-deficient Mice. Next,
cytokine gene expression in liver and spleen tissue from
C57BL/6 and CD7-deficient mice was quantified by RN-
ase protection assays. C57BL/6 (n 5 3) and CD7-deficient
(n 5 3) animals were treated with low-dose LPS plus D-gal
for either 0 or 6 h. The expression of various proinflam-
matory cytokine genes in liver and spleen are shown in
Fig. 3.
Marked increases in TNF-a, IFN-g, and IL-6 steady-
state mRNA levels were observed in liver tissues from
C57BL/6 control mice treated with LPS plus D-gal for 6 h
(P , 0.05; Fig. 3 A). As seen in the control mice, expres-
sion of TNF-a and IL-6 mRNA were also significantly el-
evated in liver tissue from CD7-deficient mice exposed to
LPS plus D-gal for 6 h, compared with pretreatment levels
(P , 0.05; Fig. 3 A). However, there was no significant in-
crease in the steady-state level of IFN-g in 6-h–treated
CD7-deficient mice versus the 0 h mice. In addition, liver
from LPS plus D-gal–treated CD7-deficient animals had
lower steady-state mRNA levels of TNF-a and IL-6
mRNA compared with those seen in C57BL/6 liver tissues
(P , 0.05). In contrast, spleen of both C57BL/6 and CD7-
deficient mice had no significant differences in TNF-a,
IFN-g, or IL-6 steady-state mRNA levels after treatment
with LPS plus D-gal for 6 h (Fig. 3 B).
Deficient IFN-g production in the liver could be due to
a lack of induction of the IFN-g inducing factors IL-12 and
IL-18 or ICE. To address these possibilities, IL-12 (p35,
Figure 2. CD7-deficient animals have diminished in vivo cytokine se-
rum levels in response to treatment with low-dose LPS and D-gal. (A)
Time course of TNF-a serum concentrations after injection of C57BL/6
control mice (j) or CD7-deficient mice (h) with LPS (1 mg) and D-gal
(8 mg). (B) Time course of IFN-g serum concentration after injection of
C57BL/6 control mice (j) and CD7-deficient mice (h) with LPS and
D-gal. Serum cytokine levels, determined by ELISA from one mouse per
time point are presented. Data shown are from an experiment that is rep-
resentative of three separate experiments performed. Statistical signifi-
cance was determined for each time point by combining data from three
experiments; *P # 0.001 when comparing C57BL/6 control mice to
CD7-deficient mice.
Figure 3. Steady-state cytokine mRNA levels in the low-dose LPS
shock model. Total RNA was extracted from liver (A and C) and spleen
(B) from C57BL/6 control (1/1, n 5 3) and CD7-deficient (2/2, n 5
3) mice 0 and 6 h after injection with low-dose LPS and D-gal. Specific
cytokine mRNA levels were quantified by RNase protection assays and
reported as percentage of GAPDH signal. Data represent the mean 6
SEM of results obtained from three mice at each time point.1014 CD7-deficient Mice Are Resistant to LPS-induced Death
p40), IL-18, and ICE steady-state mRNA expression in
liver was determined by RNase protection assays. IL-18
and ICE mRNA expression in liver (Fig. 3 C) was deter-
mined after 6 h of exposure to LPS plus D-gal. There was
no difference between C57BL/6 control mice (n 5 3) and
CD7-deficient mice (n 5 3) in constitutive or LPS-induced
steady-state levels of IL-18 and ICE mRNA expression. At
the 6-h time point no significant induction in p35 or p40
IL-12 mRNA was detected in CD7-deficient or control mice.
In addition, no difference in constitutive or LPS-induced
steady-state levels of either IL-12 mRNA was observed be-
tween C57BL/6 control mice and CD7-deficient mice.
CD7-deficient Splenocytes Responded Normally to IL-18
with IFN-g Production. Splenocytes from C57BL/6 control
mice (n 5 3) and CD7-deficient mice (n 5 3) were cul-
tured in vitro for 72 h with a wide dose range of IL-12,
IL-18, and IL-12 plus IL-18 (Fig. 4). As shown in Fig. 4 A,
IL-12 alone did not induce IFN-g production by spleno-
cytes from either C57BL/6 control or CD7-deficient mice.
IL-18 alone induced a low level of IFN-g production in
splenocyte cultures from both C57BL/6 control and CD7-
deficient mice (P 5 NS) (Fig. 4 B). When IL-12 and IL-18
were combined to stimulate IFN-g production (Fig. 4 C),
an enhanced induction in IFN-g production was observed
for both C57BL/6 splenocytes and CD7-deficient spleno-
cytes. There was no significant difference in the level of
IFN-g stimulated by both cytokines in splenocyte cultures
from C57BL/6 versus CD7-deficient mice.
CD7-deficient Mice Have Reduced Numbers of Liver NK1.11/
CD31 T Cells. NK1.11/CD31 T cells have been recently
reported to be major producers of IFN-g and key effector
cells in the pathogenesis of lethal shock syndromes (23, 24).
Thus, we isolated liver mononuclear cells from C57BL/6
control and CD7-deficient mice and performed pheno-
typic analysis with respect to CD3 and NK1.1 expression.
Three independent experiments comparing C57BL/6 and
CD7-deficient mice were performed by pooling of liver
mononuclear cells from two to five animals per experiment.
There was no difference in the absolute number of liver
lymphocytes isolated from C57BL/6 versus CD7-deficient
livers (Fig. 5). We observed a significant reduction in the
percentage and number of NK1.11/CD31 cells in livers
from untreated CD7-deficient mice (P , 0.05). In con-
trast, the percentage and absolute number of traditional NK
cells (NK1.11/CD32) and T cells (NK1.12/CD31) per
liver in C57BL/6 control and CD7-deficient mice were
similar. CD7-deficient livers also had an increase in the
number of B2201 B cells compared with C57BL/6 con-
trols (Fig. 5).
Discussion
In this study we have shown that CD7-deficient mice
are resistant to death in both the high-dose and the low-
dose LPS-induced models of shock. Using the low-dose
LPS model we demonstrated decreased induction of serum
TNF-a and IFN-g, decreased liver IL-6, TNF-a and IFN-g
steady-state mRNA levels, and normal liver IL-12, IL-18,
and ICE mRNA levels in CD7-deficient mice compared
with control mice. Moreover, we showed that CD7-defi-
cient lymphocytes responded normally to IL-12 and IL-18
with regard to IFN-g production. Finally, resistance of
CD7-deficient mice to LPS-induced shock was associated
with a low number of resident effector NK1.11/CD31 T
cells in liver of CD7-deficient mice.
The CD7-deficient mouse is unique among homologous
recombinant mouse strains with respect to its responses in
low- and high-dose LPS-induced shock syndromes. Similar
to ICAM-1 deficient, ICE-deficient, and TNFRII-defi-
cient mice (19, 20, 22), CD7-deficient mice are partially
resistant to LPS-induced death in the high-dose shock
Figure 4. In vitro splenocyte IFN-g response to stimulation with
IL-12 and IL-18. Splenocytes from C57BL/6 control mice (n 5 3) and
CD7-deficient mice (n 5 3) were isolated and incubated with a dose-
curve of IL-12 (A), IL-18 (B), or IL-12 plus IL-18 (C) for 72 h. Culture
supernatants were assayed for IFN-g by ELISA. Similar results were
found for IL-12 and IL-18, and IL-12 plus IL-18 induced proliferation of
C57BL/6 and CD7-deficient splenocytes (data not shown). Data are the
mean 6 SEM for three animals.1015 Sempowski et al. Brief Definitive Report
model. Moreover, CD7-deficient mice are fully resistant to
LPS-induced death in the low-dose shock model, similar to
IFN-gR–deficient and TNFRI-deficient mice (14, 18)
(Table I).
Recent studies have reported that murine liver contains a
unique population of a/b T cells that have intermediate
TCR expression and are positive for the NK1.1 antigen
(23). These NK1.11/CD31 T cells are phenotypically and
functionally distinct from NK 1.12 T cells, which are high in
TCR expression, and from CD32 NK cells, which are TCR
negative (23). This population of NK1.11/CD31 liver T cells
has been suggested to be autoreactive (25, 26), a major
source of IFN-g production, and key effector cells in the
pathogenesis of lethal shock syndromes (23, 24, 27). These
studies further revealed that LPS activates NK1.11/CD31
T cells via IL-12 production by Kupffer cells, resulting in the
hepatotoxicity observed in septic shock (27). Moreover, de-
pletion of these cells significantly decreased mortality in the
IL-12–primed LPS-induced shock syndrome (24).
We have found a significant reduction in the percentage
and absolute number of NK1.11/CD31 cells in livers from
untreated CD7-deficient mice versus age-matched control
mice (Fig. 5). These data suggested that the CD7 molecule
may play a critical role in development, function, and/or
migration of liver NK1.11/CD31 T cells. The ontogeny of
NK1.11/CD31 T cells is currently unknown; however, it
is clear that they are a functionally and phenotypically distinct
subset of cells (23). That CD7-deficient animals have selec-
tively diminished numbers of CD31/NK1.11 T cells with
normal numbers of CD32/NK1.11 NK cells and CD31/
NK1.12 T cells, also suggests that the CD31/NK1.11 T cell
subset may be a distinct cell lineage. We hypothesize that
CD7, which is expressed early in T and NK cell ontogeny
(7), may play a role in development and/or migration of
NK1.11 T cells in the liver. Decreased numbers of these T
cells in the livers of CD7-deficient mice may result in
blunted cytokine production and be sufficient to protect
mice from both high- and low-dose LPS-induced shock.
Thus, CD7-deficient mice are unique in their resistance
to both high-dose and low-dose LPS-induced shock mod-
els. Our data suggest that CD7 is an essential molecule that
is involved in the lethal cellular and molecular events lead-
ing to low-dose LPS-induced hepatocyte necrosis/apop-
tosis, and to ischemia/reperfusion injury in high-dose
LPS-induced shock. Understanding the role of CD7 in
LPS shock syndromes and in NK1.11 T cell maturation
and function may spur the development of new treatments
for endotoxic shock syndrome in humans.
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Figure 5. CD7-deficient animals have decreased percentages and abso-
lute numbers of liver NK1.11/CD31 T cells. Flow cytometric analysis of
isolated liver mononuclear cells from C57BL/6 and CD7-deficient mice
was performed as described in Materials and Methods. A minimum of 104
lymphocyte-gated events were analyzed per sample. Panel A shows per-
centages of CD31/NK1.11 T cells, CD32/NK1.11 NK cells, CD31/
NK1.12 T cells, and B2201 B cells. In panel B, the total number of
mononuclear cells isolated per liver was determined and used to calculate
the absolute number per liver of CD31/NK1.11 T cells, CD32/NK1.11
NK cells, CD31/NK1.12 T cells, and B2201 B cells. Data are the mean 6
SEM from three experiments with liver mononuclear cells from two to
five animals pooled per group, per experiment. *P , 0.05 when compar-
ing C57BL/6 control mice to CD7-deficient mice.
Table I. Sensitivity or Resistance of Genetically Deficient Mice in 
Endotoxic Shock Models
Mouse strain High-dose LPS Low-dose LPS
C57BL/6 control Sensitive* Sensitive
ICAM-1–deficient Resistant‡ Sensitive
ICE-deficient Resistant Sensitive
TNF-RII–deficient Partially resistant Sensitive
IL-1b–deficient Sensitive Sensitive
TNF-RI–deficient Sensitive Resistant
IFN-gR–deficient Sensitive Resistant
CD7-deficient Partially resistant Resistant
*Sensitive means animals developed shock and succumbed to LPS in-
jection.
‡Resistance means animals are resistant to the effects of LPS and survive
LPS or LPS plus D-gal injections.1016 CD7-deficient Mice Are Resistant to LPS-induced Death
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